Archive | December, 2016

RESI Partnering Opens Soon: Look Who You Can Meet

1 Dec

Lauren Schulkamp, Business Development Manager-RESI Conference Series, LSN

lauren-wp

Partnering serves as the foundation of any successful investment conference. The RESI Partnering Platform, combined with the sheer quantity and diversity of investors attending RESI, provides you with a one-of-a-kind partnering experience. Below, you can view that breadth of investors who have registered to attend.

Next Monday (December 5th), RESI Partnering will launch. RESI attendees can use the platform to find other attendees based on specific areas of common interest: sector, subsector, indication, phase of development, investment stage, capital structure preference, etc. The RESI Partnering Platform also maintains investor profiles that are populated by LSN’s propitiatory investor data.  Through intensive research and one-on-one dialogues with the investors themselves, we are able to gather the most accurate, up-to-date investment preferences from the attending investors, providing you with the ultimate opportunity for powerful and effective dialogue.

Several advantages come with registering early for partnering events:

  1. To ensure that you will have access to partnering.
  2. Get a head start on finding investors who are a fit for your technology.
  3. Put yourself on top and start sending out meeting requests.

Remember: many investors fill up their schedules well in advance!

With partnering going live on Monday, the best time to register for the event is now. We have over 360 investors signed up so far, take a look at who you can meet with:

wp

Massachusetts Entrepreneur Visa Program Brings $185 Million in Investment

1 Dec

By Bill Brah, Assistant Vice Provost for Research and Executive Director, Venture Development Center

billcc

In March, we shared an introduction to the Global Entrepreneur in Residence (GEIR) Program at UMass Boston’s Venture Development Center, which supports entrepreneurs in the life sciences and other sectors by providing H1B visas for founders. As GEIR has gained traction, LSN is excited to revisit GEIR to track its progress.

First report on how the program is working

With national startup visa legislation stymied in a bitterly divided Washington D. C., Massachusetts is showing that something constructive is possible. Two years ago, it created the Global Entrepreneur-in-Residence Program to retain foreign grads of local universities who are launching startup companies. The program was developed by the Massachusetts Technology Collaborative, and formed as a public-private partnership by Governors Deval Patrick (D) and Charlie Baker (R), working with members of the innovation community including Flybridge Capital Partners, Silicon Valley Bank and Goodwin Procter.

The University of Massachusetts Venture Development Center, which is leading the pilot program, has released statistics (below) on how the program is working. It provides the first concrete evidence of how a national startup visa is expected to benefit the country.

The Global Entrepreneur-in-Residence program gives entrepreneurs H-1B visas sponsored by the University of Massachusetts. Unlike private employers, a university is exempt from the annual H-1B visa quota. The university sponsors an entrepreneur for part-time work at its Venture Development Center and the entrepreneur spends the rest of their time advancing their startup company to the point where the company can sponsor the H-1B visa.

Strong demand among entrepreneurial grads of many universities and countries

The program has been selective. It reported that 67 entrepreneurs applied to the program; 23 or 34% of the entrepreneurs were accepted. All received visas. Seven entrepreneurs have already “graduated” from the program with visas independent of the University of Massachusetts.

The entrepreneurs represent 16 different countries, India leading with 37%. The entrepreneurs attended 15 different universities, with Harvard and MIT leading with 35% of the entrepreneurs. The program has also drawn entrepreneurs from universities outside Massachusetts including Stanford, Columbia and Carnegie Mellon. Ten of the 23 entrepreneurs are software engineers. The rest are finance, marketing and management majors.

Entrepreneur’s companies have had fundraising success, and are adding employees

The entrepreneurs’ 20 companies have raised a total of $185,512,265 in private investment, and have a headcount of 416 employees. The companies include both newly formed and growing companies. All have had fundraising success, and are adding employees. Fourteen or 70% of the 20 companies are newly formed; the companies have raised $10,313,000 in private investment and have 61 employees. Six companies are at the growth stage. They have 355 employees and have raised $175,199,265.

Other states following Massachusetts lead

Encouraged by the potential, the U.S. Citizenship and Immigration Services has proposed a new rule which would allow certain international entrepreneurs to be considered for temporary permission to be in the US. However, investors are pushing for more flexibility before the rule is adopted.

Meanwhile, the Venture Development Center has opened its application process for 2017 and plans to accept 15 more entrepreneurs. And other state universities in Colorado, New York and California have followed Massachusetts in adopting global entrepreneur programs.

RESI San Francisco Panel Announcement: Diagnostic Investors

1 Dec

By Cole Bunn, Senior Research Analyst, LSN

cole-wp

As we are quickly approaching RESI@JPM, LSN is happy to announce the Diagnostic Investors panel. Entrepreneurs seeking to secure funding for their diagnostic technologies arguably have the toughest job of all the early-stage biotech/medtech folks, given the wide variety of diagnostic technologies and services along with a complex regulatory and reimbursement system.

Whether you are looking for guidance on how to court a venture investor or how to engage a strategic partner, you can hear from both on how to best prepare to present to and work with organizations like theirs.

Diagnostics panelists will include the following:

The panelists will share their perspective and tactical guidance for shepherding a diagnostic at the early stages of development through the dynamic healthcare environment to an eventual exit.

By registering for RESI San Francisco, you’ll be able to listen to the Diagnostics panel live in person, and experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.

resi-san-francisco-2017

Hot Investor Mandate 1: Precision Medicine Fund Seeks Diagnostic & Data Opportunities

1 Dec

A medical technology venture firm based in Massachusetts makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. The firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: Canada Fund Seeks Medtech and Diagnostics, Software Component Preferred

1 Dec

An investment firm based in Toronto, Canada is actively looking for new investments in the life science sector, especially medical technology. The firm’s current fund focuses on pre and post Series A investments with the ability to do follow-on funding. The investment size can range from $100K to over $1M and up to $2-4M with follow-on funding. The firm typically co-invests and will lead investments depending on the occasion and size of the round. Investment can be in form of equity, whereas convertible loan and other capital structures will be considered. The new fund looks to invest in 10-20 companies. The firm focuses on companies based in Canada, but it will also look at opportunities in the US.

In the life sciences, the firm is currently looking for new investments in the medical technology, diagnostics, and healthcare IT sectors with a particular interest in medical devices with a software component. The firm is interested in all classes of medical devices and is indication agnostic. The firm is focused on preclinical to clinical stage technology and is focused on technology that requires an FDA regulatory pathway. Thus, the firm is not interested in wearables or consumer connected devices. The firm will consider therapeutics companies from time-to-time, however, therapeutics is not the firm’s focus. Historically, the firm was active in a company developing blood-testing platform for infectious diseases.

The firm focuses on investments in private companies with an experienced management team and growth potential. The firm will take a board seat based on case-by-case basis, though is not the requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Corporate VC Seeks Medtech for Home Care and Chronic Diseases

1 Dec

The venture capital subsidiary of a large healthcare corporation based in Europe invests to take minority stakes in innovative technology start-ups. The firm can lead or co-invest with other investors. Typical allocations are made in equity and range from €1-10 million. The firm is currently seeking new opportunities across a wide geography, including Western Europe, North and South America and Asia.

The firm focuses on medical devices and health IT products that present novel treatment, monitoring, or self-care strategies in home settings. In general, the firm is interested in chronic diseases, particularly in COPD, sleep apnea, renal diseases, and Parkinson’s disease. The technology should complement its current portfolio and fit the parent group’s long-term goals. The firm specializes in early stage projects from concept to clinical development.

The firm is looking for competent management teams with some previous experience in taking a company to an exit and understanding of the negotiations throughout the process. The firm typically takes a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Private Wealth Firm Invests in Digital Health, Informatics, and Therapeutics

1 Dec

A private investment firm based in California, USA invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

Historically, the firm has invested in technology and life sciences. Today, the firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. The firm is agnostic in terms of subsectors and indications, including orphan indications. The firm will only consider technologies with proof of concept and strong scientific rationale. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm takes a board seat in some cases, and prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com